EP0904293A1 - Antagoniste d'interleukine-5 - Google Patents

Antagoniste d'interleukine-5

Info

Publication number
EP0904293A1
EP0904293A1 EP97921538A EP97921538A EP0904293A1 EP 0904293 A1 EP0904293 A1 EP 0904293A1 EP 97921538 A EP97921538 A EP 97921538A EP 97921538 A EP97921538 A EP 97921538A EP 0904293 A1 EP0904293 A1 EP 0904293A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
modified
xaa
arg
acidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97921538A
Other languages
German (de)
English (en)
Other versions
EP0904293A4 (fr
Inventor
Angel Lopez
Matthew Vadas
Frances Shannon
Stan Bastiras
Allan William Hey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Hospira Adelaide Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Bresagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd, Bresagen Ltd filed Critical Medvet Science Pty Ltd
Publication of EP0904293A1 publication Critical patent/EP0904293A1/fr
Publication of EP0904293A4 publication Critical patent/EP0904293A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to modified and variant forms of Interleuk.in-5 molecules capable of antagonizing or reducing the activity of IL-5 and their use in ameliorating, abating or otherwise reducing the aberrant effects caused by native or mutant forms of IL-5.
  • IL-5 One particularly important haemopoietic growth factor is IL-5.
  • This molecule is a lymphokine secreted by T-cells and mast cells and is a disulfide-linked homodimeric glycoprotein.
  • the human form of this molecule comprises 114 amino acids per monomer.
  • IL-5 consists of a bundle of four ⁇ -helices in an up-up, down-down array. The phenomenon of D-helix swapping whereby one bundle is built up of three helices coming from one monomer and a fourth helix which is contributed by the second monomer is unique to IL-5.
  • the IL-5 molecule also contains two short anti-parallel ⁇ -strands located between helices A and B and helices C and D.
  • Human and murine IL-5 receptors comprise two different chains, the ⁇ and ⁇ -subunits. Human IL-5 binds to the ⁇ -subunit but the binding affinity is increased upon association with the ⁇ -chain The ⁇ -chain is shared by other cytokines such as GM-CSF and 1L-3
  • IL-5 is a haemopoietic growth factor with selectivity for production and activation of human eosinophils
  • one aspect of the present invention contemplates a modified IL-5 comprising a sequence of amino acids within a first ⁇ -helix wherein one or more exposed amino acids in said first ⁇ -hehx having acidic or acidic-like properties are substituted with a basic amino eicid residue or a non-acidic amino acid residue
  • the IL-5 which is subject to modification is generally of mammalian origin such as from humans, primates, livestock animals (eg sheep, cows, pigs, horses), laboratory test animals (eg mice, rats, guinea pigs, rabbits), companion animals (eg dogs, cats) and captive wild animals (eg kangaroos, foxes, deer) Most preferably, the IL-5 is of human origin
  • livestock animals eg sheep, cows, pigs, horses
  • laboratory test animals eg mice, rats, guinea pigs, rabbits
  • companion animals eg dogs, cats
  • captive wild animals eg kangaroos, foxes, deer
  • the IL-5 is of human origin
  • the modified IL-5 of the present invention may be glycosylated or unglycosylated and does not interfere with GM-CSF or IL-3 activity
  • the present invention is directed to a modified human LL-5 molecule comprising a sequence of amino acids wherein Glu at amino acid position 13 (or its equivalent position) in a first ⁇ -hehx is replaced by Arg or Lys or a chemical equivalent or derivative thereof
  • Glu at amino acid position 13 (or its equivalent position) in a first ⁇ -hehx is replaced by Arg or Lys or a chemical equivalent or derivative thereof
  • An alternative substitution may also be made using non-acidic amino acid residues such as but not limited to Gin and Asn or their chemical equivalent or derivatives
  • a "derivative" may be a naturally occurring or synthetic amino acid residue
  • modified IL-5 molecules act as antagonists of the native form of IL-5
  • modified is considered herein synonymous with terms such as “variant”, “derivative” and “mutant”.
  • the present invention is particularly directed to a modified IL-5 which exhibits specific antagonism of LL-5 mitogenic effects such as observed in vitro.
  • the modified LL-5 molecules may be glycosylated or unglycosylated and do not interfere with GM-CSF or LL- 3 activity.
  • another aspect of the present invention is directed to an IL-5 antagonist said antagonist comprising an IL-5 molecule having an amino acid sequence in its first ⁇ -helix wherein one or more exposed amino acids in said first ⁇ -helix having acidic or acidic-like properties are substituted with a basic amino acid residue or a non-acidic amino acid residue
  • the present invention provides an antagonist of IL-5 said antagonist comprising an IL-5 molecule with Gin at position 13 (or its equivalent position) in a first ⁇ - helix substituted by Arg or Lys or a chemical equivalent or derivative thereof.
  • an alternatively substitution may also be made using non-acidic amino acid residues such as but not limited to Gin and Asn or their chemical equivalents or derivatives.
  • the modified IL-5 molecule of the present invention is preferably in recombinant or synthetic form and, with the exception of the amino acid substitution(s) in the first ⁇ -helix, the amino acid sequence of the IL-5 may be the same as the naturally occurring molecule
  • IL-5 may carry single or multiple amino acid substitutions, deletions and/or additions to the native amino acid sequence. It is then referred to as a "mutant" IL-5.
  • the structure of the first ⁇ -helix of IL-5 has been determined at 2.4 angstrom resolution by X-ray crystallography and comprises amino acid residues 7 to 27 or their equivalents (see
  • the modified LL-5 of the present invention may or may not comprise a leader sequence.
  • the nucleotide and corresponding amino acid sequence for the modified IL-5 having Arg in position 13 is shown in SEQ ID NOs: 1 and 2 and Figure 1.
  • the leader sequence is shown ES ammo acids 1 to 6 (Met His Tyr His His His [SEQ ID NO 3]) Consequently, amino acids 7 to 27 are shown as amino acids 13-33 in SEQ ID NOs 1 and 2 and in Figure 1 Reference to amino acids 7 to 27 is taken as amino acid residue numbers in a molecule without a leader sequence
  • the amino acid sequence for amino acids 7 to 27 is shown as SEQ ID NO 4 except that amino acid 13 is represented as Xaa
  • Xaa is preferably a basic amino acid residue or a non-acidic amino acid residue
  • unglycosylated form means that the molecule is completely unglycosylated such as when expressed in recombinant form in a prokaryotic organism (e g h col ⁇ Alternatively, a glycosylation-deficient mammalian cell may be used or complete deglycosylation may occur in vitro using appropriate enzymes Different glycosylation patterns are encompassed by the present invention such as when recombinant molecules are produced in different mammalian cells
  • an “exposed” amino acid is taken herein to refer to an amino acid on a solvent-exposed or oater portion of an ⁇ -hehx compared to those amino acids orientated towards the inside of the molecule
  • An acidic amino acid includes, for example, Glu and Asp Preferred basic amino acids are Arg and Lys Preferred non-acidic amino acids are Gin and Asn
  • a modified IL-5 characterised by (I) comprising a sequence of amino acids within a first ⁇ -helix,
  • the present invention provides an LL-5 antagonist characterised by: (i) comprising a sequence of amino acids within a first ⁇ -helix; (ii) having one or more exposed amino acids in said ⁇ -helix which have acidic or acidic-like properties being substituted by a basic amino acid residue or a non-acidic amino acid residue,
  • the IL-5 mutant may be in glycosylated or unglycosylated form.
  • This aspect of the present invention is predicated in part on the finding that a mutation in amino acid 13 (Glu) of human (h) IL-5 to Arg results in the hIL-5 variant being capable of antagonising IL-5 mitogenic effects in vitro.
  • This variant is referred to herein as "IL-5 Arg 13 " or "E13 R” .
  • Such a variant would be unable to bind to high affinity receptors but would still able to fully bind the low affinity ⁇ chain of the IL-5 receptor.
  • the IL-5 Arg 13 mutant acts as an antagonist, preventing the stimulatory effect of native IL- 5.
  • IL-5 Arg 13 antagonist is in reducing or otherwise antagonising IL-5-mediated stimulation and activation of eosinophils in vivo or in vitro.
  • the antagonist may also be able to antagonise effects caused by a mutated, endogenous IL-5.
  • the present invention extends to a range of other IL-5 mutants such as IL-5 Lys 13 , IL-5 Gin 13 and IL-5 Asn 13 as well as functionally equivalent mutants.
  • the nucleotide and corresponding amino acid sequence for IL-5 Arg 13 (E13R) are shown in SEQ ID NOs: 1 and 2.
  • the present invention extends, in a particularly preferred embodiment, to an isolated polypeptide having an amino acid sequence substantially as set forth in SEQ ID NO:2 or a genetic sequence encoding same having a nucleotide sequence substantially as set forth in SEQ ID NO: 1.
  • an IL-5 variant comprising an amino acid sequence in the first ⁇ -helix of said IL-5:
  • Xaa is a basic or non-acidic amino acid residue preferably selected from the group consisting of Arg, Lys, Gin and Asn and wherein said variant IL-5 acts as an antagonist for at least one property of the corresponding native IL-5
  • the amino acid sequence defined by SEQ ID NO-4 corresponds to amino acid residues 7 to 27 of human IL-5
  • Xaa is Xaa" wherein n is amino acid position 13 of human IL-5
  • Xaa n is Arg 13 or its equivalent
  • the present invention contemplates an IL-5 antagonist comprising a polypeptide or chemical equivalent thereof comprising amino acids 7 to 27 of the first ⁇ - helix of human LL-5 with the proviso that one or more exposed amino acids in said first ⁇ - helix having acidic or acidic-like properties are substituted by a basic amino acid residue or a non-acidic amino acid residue.
  • the acidic or acidic-like amino acid residue if Glu or Asp and is replaced by Arg, Lys, Gin or Asn
  • the acidic or acidic-like amino acid residue is replaced by Arg
  • amino acid sequence of the modified IL-5 is as set forth in SEQ ID NO:2.
  • the present invention is directed to an IL-5 antagonist comprising a modified IL-5 molecule having the following amino acid sequence in its first ⁇ -helix Thr Ser Ala Leu Val Lys Xaa Thr Leu Ala Leu Leu Ser Thr His Arg Thr Leu Leu He Ala [SEQ ID NO:4]
  • Xaa is Arg; or an IL-5 molecule having a single or multiple mutation in its first ⁇ -helix giving functionally similar antagonistic properties to the mutation wherein Xaa is Arg.
  • the mutation in the LL-5 molecule may be a single or multiple amino acid substitution, deletion and/or addition or may be an altered glycosvlation pattern amongst other mutations.
  • the IL-5 antagonist comprises an amino acid sequence as set forth in SEQ ID NO: 2.
  • the IL-5 antagonists of the present invention and in particular IL-5 Arg 13 are useful inter alia in the treatment of allergy, some myeloid leukemias (such as eosinophilic myeloid leukaemia), idiopathic eosinophilic syndrome, allergic inflammations such as asthma, rhinitis and skin allergies by preventing or reducing IL-5-mediated activation of eosinophils.
  • myeloid leukemias such as eosinophilic myeloid leukaemia
  • idiopathic eosinophilic syndrome idiopathic eosinophilic syndrome
  • allergic inflammations such as asthma, rhinitis and skin allergies by preventing or reducing IL-5-mediated activation of eosinophils.
  • the present invention contemplates a method of treatment comprising the administration to a mammal of an effective amount of a modified LL-5 as hereinbefore defined and in particular LL-5 Arg 13 for a time and under conditions sufficient for effecting said treatment.
  • the treatment is in respect of the treatment of allergy, some myeloid leukemias (such as eosinophilic myeloid leukaemia), idiopathic eosinophilic syndrome, allergic inflammations such as asthma, rhinitis and skin allergies.
  • myeloid leukemias such as eosinophilic myeloid leukaemia
  • idiopathic eosinophilic syndrome allergic inflammations such as asthma, rhinitis and skin allergies.
  • the mammal to be treated is a human, primate, livestock animal, companion animal or laboratory test animal. Most preferably, the mammal is a human.
  • a single modified IL-5 may be administered or a combination of variants of the same IL-5
  • a range of IL-5 variants could be used such as a combination selected from two or more of LL-5 Arg 13 , IL-5 Lys 13 , IL-5 Gin 13 and IL-5 Asn ⁇
  • the IL-5 variants of the present invention are particularly useful in treating eosinophiha and conditions resulting therefrom such as asthma Administration is preferably by intravenous administration but a range of other forms of administration are contemplated by the present invention including via an implant device or other form allowing sustained release of the IL-5 variant, in a nebuliser form or nasal spray
  • Modified forms of IL-5 permit entry following topical application are also encompassed by the present invention
  • the present invention further provides a range of other derivatives of IL-5
  • Such derivatives include fragments, parts, portions, mutants, homologues and analogues of the LL-5 polypeptide and corresponding genetic sequence
  • Derivatives also include single or multiple amino acid substitutions, deletions and/or additions to LL-5 or single or multiple nucleotide substitutions, deletions and/or additions to the genetic sequence encoding IL-5
  • Derivatives also contemplated modifications to resident nucleotides Alteration of the nucleotides may result in a corresponding altered amino acid sequence or altered glycosylation patterns amongst other effects
  • “Additions" to amino acid sequences or nucleotide sequences include fusions with other peptides, polypeptides or proteins or fusions to nucleotide sequences
  • Reference herein to "IL-5" includes reference to all derivatives thereof including functional derivatives or IL-5 immunologically interactive derivatives All such derivatives would be in addition to the modifications to the first ⁇ -hehx contemplated above Accordingly, such derivatives would be to
  • Analogues of IL-5 contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues
  • the present invention further contemplates chemical analogues of IL-5 capable of acting as antagonists or agonists of IL-5 or which can act as functional analogues of IL-5
  • Chemical analogues may not necessarily be derived from IL-5 but may share certain conformational similarities Alternatively, chemical analogues may be specifically designed to mimic certain physiochemical properties of IL-5
  • Chemical analogues may be chemically synthesised or may be detected following, for example, natural product screening
  • glycosylation variants from a completely unglycosylated molecule to a fully glycosylated molecule and from a naturally glycosylated molecule to molecules with an altered glycosylation pattern Altered glycosylation patterns may result from expression of recombinant molecules in different host cells
  • modifications may be important to stabilise the modified IL-5 molecules if administered to an individual or when used as a diagnostic reagent
  • the modifications may also add, complement or otherwise facilitate the antagonistic properties of the modified IL-5 molecules
  • Reference herein to a "modified" IL-5 therefore, includes reference to an IL-5 with an altered amino acid sequence in the first ⁇ -hehx as well as, where appropriate, a range of glycosylation variants, amino acid variations in other parts of the molecule, chemical modifications to the molecule as well as fusion molecules
  • the present invention also provides a pharmaceutical composition comprising the modified IL-5 molecules as hereinbefore defined or combinations thereof
  • the present invention contemplates a pharmaceutical composition
  • a pharmaceutical composition comprising a a modified IL-5, said modified IL-5 comprising a sequence of amino acids with a first ⁇ - hehx wherein one or more exposed amino acids in said first ⁇ -hehx having acidic or acidic- hke properties are substituted with a basic amino acid residue or non-acidic amino acid lesidue, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a modified human IL-5 or a mammalian homologue thereof said modified LL-5 comprising a sequence of amino acids in a first ⁇ -hehx of
  • Xaa is a basic non-acidic amino acid residue preferably selected from Arg, Lys, Gin and Asn, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents
  • Xaa is Xaa" where n is amino acid position 13
  • Xaa is Arg
  • the present invention contemplates a pharmaceutical composition capable of antagonising IL-5, said composition comprising a modified IL-5 having an amino acid sequence in its first ⁇ -hehx
  • Xaa is selected from Arg, Lys, Gin and Asn
  • Xaa is Arg
  • compositions may also contain other pharmaceutically active molecules including other LL-5 variants
  • active agents or “active compounds”.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, mannitol glycine or suitable mixtures thereof.
  • the preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • Mannitol glycine is a particularly useful formulation especially when the modified IL-5 molecules are given as an intravenous drip.
  • the present invention also extends to forms suitable for inhaling such as a nasal spray as well as in nebulizer form.
  • sustained release compositions may be formulated as well as a range of implant devices.
  • the molecules may also be given as a cream, lotion or gel.
  • a suitable carrier for a cream, lotion or gel includes a polyol such as but not limited to glycerol, propylene glycol, liquid polyethylene glycol and the like.
  • Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, and antibacterial and antifungal agents.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated by the present invention. Supplementary active ingredients can also be incorporated into the compositions.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition involving or facilitated by aberration of IL-5 molecules or levels of IL-5.
  • the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed.
  • a unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 ⁇ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 ⁇ g to about 2000 mg/ml of carrier.
  • the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
  • the pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating modified IL-5 expression or modified IL-5 activity
  • the vector may, for example, be a viral vector
  • Still another aspect of the present invention is directed to antibodies to the modified IL-5 molecules and their derivatives
  • Such antibodies may be monoclonal or polyclonal and may be specifically raised to modified IL-5 or derivatives thereof
  • a modified IL-5 or its derivatives may first need to be associated with a carrier molecule
  • the antibodies and/or recombinant modified IL-5 or its derivatives of the present invention are particularly useful as therapeutic or diagnostic agents
  • a modified IL-5 and its derivatives can be used to screen for naturally occurring antibodies to IL-5 These may occur, for example in some autoimmune diseases
  • specific antibodies can be used to screen for a modified or mutant IL-5
  • Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA Knowledge of LL-5 levels may be important for diagnosis of certain cancers or a predisposition to cancers or for monitoring certain therapeutic protocols when modified IL-5 molecules are employed
  • Antibodies to modified IL-5 of the present invention may be monoclonal or polyclonal Alternatively, fragments of antibodies may be used such as Fab fragments Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool for assessing apoptosis or monitoring the program of a therapeutic regimen
  • modified IL-5 proteins can be used to screen for modified IL-5 proteins
  • the latter would be important, for example, as a means for screening for levels of modified LL-5 in a cell extract or other biological fluid or purifying modified IL-5 made by recombinant means from culture supernatant fluid.
  • Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays and ELISA.
  • second antibodies (monoclonal, polyclonal or fragments of antibodies or synthetic antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody.
  • An antibody as contemplated herein includes any antibody specific to any region of modified IL-5.
  • Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays.
  • the methods of obtaining both types of sera are well known in the art.
  • Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of modified IL-5 or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques.
  • antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.
  • the use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product.
  • the preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art.
  • Another aspect of the present invention contemplates a method for detecting modified LL-5 in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for modified IL-5 or its derivatives or homologues for a time and under conditions sufficient for an antibody-modified IL-5 complex to form, and then detecting said complex.
  • the present invention also contemplates genetic assays such as involving PCR analysis to detect a modified IL-5 gene or its derivatives
  • Alternative methods include direct nucleotide sequencing or mutation scanning such as single stranded conformation polymorphism analysis (SSCP) as well as specific ohgonucleotide hybridisation
  • nucleic acid molecules encoding a modified IL-5 of the present invention
  • nucleic acid molecules may be DNA or RNA
  • genomic DNA or cDNA RNA forms of the nucleic acid molecules of the present invention are generally mRNA
  • nucleic acid molecules of the present invention are generally in isolated form, they may be integrated into or hgated to or otherwise fused or associated with other genetic molecules such as vector molecules and in particular expression vector molecules
  • Vectors and expression vectors are generally capable of replication and, if applicable, expression in one or both of a prokaryotic cell or a eukaryotic cell
  • prokaryotic cells include L coh, Bacillus sp and Pseudomonas sp
  • Preferred eukaryotic cells include yeast, fungal, mammalian and insect cells
  • another aspect of the present invention contemplates a genetic construct comprising a vector portion and a mammalian and more particularly a human modified LL-5 gene portion, which modified IL-5 gene portion is capable of encoding an modified IL-5 polypeptide or a functional or immunologically interactive derivative thereof
  • the modified IL-5 gene portion of the genetic construct is operably linked to a promoter on the vector such that said promoter is capable of directing expression of said modified IL-5 gene portion in an appropriate cell
  • modified LL-5 gene portion of the genetic construct may comprise all or part of the gene fused to another genetic sequence such as a nucleotide sequence encoding glutathione-S-transferase or part thereof - 1 !
  • another aspect of the present invention contemplates an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a modified IL-5, said modified IL-5 comprising a sequence of amino acids with a first ⁇ -helix wherein one or more exposed amino acids in said first ⁇ -helix having acidic or acidic-like properties are substituted with a basic amino acid residue or a non-acidic amino acid residue
  • sequence of nucleotides encodes a human modified IL-5 or a mammalian homologue which comprises a sequence of amino acids in a first ⁇ -helix of
  • Xaa is a basic or non-acidic amino acid residue preferably selected from Arg, Lys, Gin and Asn and wherein said modified IL-5 exhibits antagonism of IL-5 induced mitogenic effects
  • Xaa is Xaa" where n is amino acid position 13
  • Xaa is Arg
  • the present invention extends to such genetic constructs and to prokaryotic or eukaryotic cells comprising same
  • the present invention further contemplates the use of a modified LL-5 as hereinbefore defined in the manufacture of a medicament in the treatment of allergy, some myeloid leukemias (such as eosinophilic myeloid leukaemia), idiopathic eosinophilic syndrome, allergic inflammations such as asthma, rhinitis and skin allergies.
  • myeloid leukemias such as eosinophilic myeloid leukaemia
  • idiopathic eosinophilic syndrome idiopathic eosinophilic syndrome
  • allergic inflammations such as asthma, rhinitis and skin allergies.
  • Tne present invention is further described by reference to the following non-limiting
  • Figure 1 is (a) a diagrammatic representation of the IL-5 E13R bacterial expression plasmid pPP3 1 and (b) DNA/amino acid sequence of MHYH 3 -IL-5 (E13R) The E13R mutation is circled
  • Figure 2 is a graphical representation showing the titration E13R for its ability to antagonise IL-5-med ⁇ ated proliferation of TFl 8 cells
  • FIG. 3A shows the titration of E13R for its ability to antagonise IL-5-med ⁇ ated proliferation of TF l -8 cells This figure also shows that E13R exhibits no detectable agonist activity
  • Figure 3B shows the failure of E13R to antagonise LL-3-med ⁇ ated proliferation of TFl 8 cells
  • Figure 3C shows the failure of E13R to antagonise GM-CSF-mediated proliferation of TFl 8 cells
  • Figure 4 is a graphical representation showing the titration of IL-3 for its mitogenic effects on TF l 8 cells and the failure of high levels of E13R to interfere with this activity
  • Figure 5 is a graphical representation showing TF l 8 proliferation assay for IL-5
  • V/T IL-5 (HI) was prepared in inclusion bodies in bacteria, dimerized in 2M urea, purified by reverse phase HPLC, concentrated in buffer exchange in PBS It was never dried down
  • LL-5 WT was prepared in the same way as WT IL-5 (HI) but after concentration, the preparation was dried down and dissolved in 25mM glycine and 1 25 mg/ml of mannitol
  • Figure 6 is a graphical representation showing the titration of GM-CSF for its mitogenic effects on TFl 8 cells and the failure of high levels of El 3R to interfere with this activity
  • FIG. 7 is a graphical representation showing that E13R inhibits IL-5 induced eosinophil antibody-dependent cell-mediated cytotoxicity
  • Figure 8 is a graphical representation showing that E13R inhibits IL-5 induced eosinophil colony formation
  • the inventors expressed and purified a charge-reversal mutant of IL-5 in which the glutamate residue at position 13 (El 3) is replaced by an arginine residue (R)
  • This mutant, E13R shows specific antagonism of IL-5 mitogenic effects in vitro.
  • this protein is presently being expressed as a fusion protein with the leader sequence MHYH 3 (MHYHHH) ISEQ ID NO: 3].
  • the leader sequence comprises amino acids 1 to 6 in SEQ ID NOs: 1 and 2.
  • FIG. 1 A diagrammatic representation of MHYH 3 and the sequence of E13R is shown in Figure 1.
  • the nucleotide and corresponding amino acid sequence of E13R is represented in SEQ ID NOs: 1 and 2.
  • Human IL-5 E13R mutant coding sequence was derived from IL-5 wild-type sequence, by site-specific mutagenesis.
  • Codon 13 was changed to an Arg codon
  • the additional codon changes listed here were based on bacterial codon preferences to promote translational efficiency in E. coli, and did not lead to amino acid changes.
  • the mutant DNA fragment was modified by polymerase chain reaction using primers to generate a sequence encoding the leader MHYH 3 at the 5' end, and a stop codon at the 3' end.
  • the amplified fragment was subcloned into the plasmid pEC611 to generate the 10 expression plasmid pPP31 , containing the trc promoter.
  • Fermentation is by the Fed-Batch method. Escherichia coli MM294/pACYCLacI q 15 transformed with the E13R-expressing plasmid pPP31 is grown in minimal medium at 37 °C. The pH is held constant at pH 7.0 during bacterial growth by the addition of NH 4 OH. Expression of IL-5 (E13R) is induced at high cell density (OD ⁇ O) either by addition of IPTG or by feeding with lactose. Induction continues for 5 hours (not including lag phase) with the protein being expressed as insoluble inclusion bodies (IBs). 20 Cells are lysed by high pressure homogenization. A primary separation of IBs from cellular debris is done by differential centrifugation, after which the IBs are washed and homogenized one more time. A final centrifugation step isolates IBs of sufficient cleanliness for refolding.
  • Escherichia coli MM294/pACYClacI q carrying pPP31 was streaked out from a 30 80 °C glycerol stock onto a minimal medium plate containing ampicillin (lOO ⁇ g/ml) and kanamycin (30 ⁇ g/ml) and grown overnight at 37°C. 2. Multiple colonies were assessed for IL-5 (E13R) expression levels by microscopic examination of 20ml shake flask cultures containing inducer, or by colony size on agar plates with or without inducer, in this instance with IPTG.
  • the selected single colony from an agar plate was transferred into 20ml of nitrogen- ⁇ ch minimal medium (2) containing amplicilhn (100 ⁇ g/ml) -I- kanamycin (30 ⁇ g/ml). The culture was grown at 37°C overnight with agitation.
  • the culture was passed five times through a Gaulin 30CD homogemzer at 13,500 psi, 30 with homogenate being cooled between passes. Homogenate was then diluted with an equal volume of RO H 2 0.
  • the IB size was redetermined by disc centrifugation.
  • the homogenate was centrifuged in a Westfalia SB-7 separator with a constant speed of 9,210 rpm at a flow rate determined by IB size.
  • the concentrate collected from this first step was diluted to ⁇ 2.5 % w/v.
  • the IB suspension was passed once through a Gaulin 30CD homogenizer at 13,500 psi.
  • the IB size was again determined by disc centrifugation.
  • the homogenate was centrifuged in a Westfalia SA-1 separator with a constant speed of 9,700 rpm at a flow rate determined by IB size.
  • IBs are initially dissolved in 6M Guanidine-HCl, containing 5-10mM dithiothretiol and buffered to pH 9.5.
  • Reduced IL-5 monomers of MHYH 3 IL-5(E13R) are then purified from non-reduced protein by Size Exclusion Chromatography (eg. Superose 12 [Pharmacia]) in 6M Guanidine-HCl, containing 5mM dithiothreitol and buffered to pH 9.5.
  • the purified reduced monomer is then refolded into dimers by dilution into 2M urea buffered to pH 9.5 at a final protein concentration of 0.01-0. 1 mg/ml.
  • Purification of correctly folded dimers is by reversed phase chromatography on a High Performance Liquid Chromatograph (HPLC) using a suitable column (eg. Brownlee butyl-silica employing 0.1 % v/v trifluoroacetic acid (TFA) in water as Buffer A and 0.1 % v/v TFA in acetonitrile as Buffer B).
  • HPLC High Performance Liquid Chromatograph
  • TFA trifluoroacetic acid
  • Buffer B 0.1 % v/v TFA in acetonitrile
  • Purified, correctly folded protein can be recovered in biological buffers after lyophilization from HPLC buffers in the presence of mannitol and glycine, added as bulking excipient agents. The identity of the purified protein can be confirmed using mass spectrometry and N-terminal sequencing.
  • the biological assay for IL-5 antagonism by E13R uses incorporation of radiolabelled thymidine to detect IL-5- ⁇ nduced cellular proliferation
  • the cell line used, TFl .8, is a subline of TFl , a human erythroleukemic cell line which expresses the receptors for IL-3 and GM-CSF.
  • TFl .8 differs from TFl in that it has been selected for expression of the IL-5 receptor. Stimulation of TFl .8 proliferation by IL-5 is inhibited by 50% in the presence of a 30-fold excess of E13R, and abolished in the presence of a 300-fold excess ( Figure 2).
  • Each cell contains lOOul of diluted standard/sample + lOOul resuspended cells Plates are incubated @ 37 D C for 72 hrs, in a humidified C0 2 incubator (48 hrs, for TF-1 & TFl .8 cells).
  • EXAMPLE 9 Antagonistic properties of E13R on eosinophils An antibody dependent cell-mediated cytotoxicity (ADCC) assay was used to determine the effect of E13R on eosinophil function This assay measures the ability of eosinophils to kill target cells radiolabelled with chromium and expressing a certain antibody recognized by the eosinophils (Vadas et al J Immunol 130 795, 1983) Blood was collected from a healthy donor and eosinophils were prepared by met ⁇ zamide gradient separation of leukocytes after removal of red cells with dextran (Vadas et al J Immunol 122 1228, 1979) The eosinophil purity exceeded 95% The eosinophils were then incubated with the target cells at a ratio of 100 eosinophils per target cell, and a fixed dose of either GM-CSF (10 ng/ml) or IL-5 (10 ng/ml) and a titration
  • Bone marrow was collected from a healthy donor and subjected to density centrifugation (Lymphoprep )
  • the mononuclear cells were plated in agar supplemented with a fixed dose of either GM-CSF (10 ng/ml) or IL-5 (10 ng/ml) and a titration of E13R
  • the cells were allowed to grow at 37°C for 2 weeks
  • the agar plates were then fixed in gluteraldehyde before the plates were stained with Luxol Fast Blue to detect eosinophilic colonies
  • Figure 8 shows that E13R dose-dependently antagonized the colony-promoting effects of LL-5, while E13R had no effect on GM-CSF stimulation of eosinophilic colony formation Values are mean and sem of triplicates
  • MOLECULE TYPE DNA (genomic)
  • FEATURE FEATURE:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formes modifiées et variantes de molécules d'Interleukine-5 capables de produire un effet antagoniste ou réducteur de l'activité de l'IL-5, et leur utilisation pour améliorer, abolir ou réduire d'une autre façon les effets aberrants provoqués par des formes endogènes ou mutantes de l'IL-5.
EP97921538A 1996-05-24 1997-05-23 Antagoniste d'interleukine-5 Withdrawn EP0904293A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO0054A AUPO005496A0 (en) 1996-05-24 1996-05-24 An interleukin-5 antagonist
AUPO0054/96 1996-05-24
PCT/AU1997/000322 WO1997045448A1 (fr) 1996-05-24 1997-05-23 Antagoniste d'interleukine-5

Publications (2)

Publication Number Publication Date
EP0904293A1 true EP0904293A1 (fr) 1999-03-31
EP0904293A4 EP0904293A4 (fr) 2002-03-06

Family

ID=3794368

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97921538A Withdrawn EP0904293A4 (fr) 1996-05-24 1997-05-23 Antagoniste d'interleukine-5

Country Status (6)

Country Link
EP (1) EP0904293A4 (fr)
JP (1) JP2001511641A (fr)
AU (1) AUPO005496A0 (fr)
CA (1) CA2256368A1 (fr)
NZ (1) NZ332946A (fr)
WO (1) WO1997045448A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084841A (ko) 1999-04-23 2002-11-11 파멕사 에이/에스 Ｉｌ5 활성을 다운-조절하는 방법
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553017B2 (en) * 1982-06-07 1986-06-26 Chr. Hansen A/S A process for the preparation of chymosin
AU690128B2 (en) * 1993-07-28 1998-04-23 Medvet Science Pty. Ltd. Haemopoietic growth factor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. V. MILBURN ET AL: "a novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interlukin-5" NATURE., vol. 363, 13 May 1993 (1993-05-13), pages 172-176, XP002186180 MACMILLAN JOURNALS LTD. LONDON., GB ISSN: 0028-0836 *
See also references of WO9745448A1 *

Also Published As

Publication number Publication date
NZ332946A (en) 2000-08-25
AUPO005496A0 (en) 1996-06-13
CA2256368A1 (fr) 1997-12-04
EP0904293A4 (fr) 2002-03-06
JP2001511641A (ja) 2001-08-14
WO1997045448A1 (fr) 1997-12-04

Similar Documents

Publication Publication Date Title
AU2018372167B2 (en) Partial agonists of interleukin-2
KR100607609B1 (ko) Ｉｌ-2 선택성 작용제 및 길항제
AU721196B2 (en) Circularly permuted erythropoietin receptor agonists
CA2232749C (fr) Facteur neurotrophique derivant de lignees de cellules tronquees de glial
US20090054336A1 (en) Binding Agent
US20100041586A1 (en) Method of improving efficacy of biological response-modifying proteins and the exemplary muteins
EP1535929A2 (fr) Facteurs stimulateurs des mégacaryocytes
BG62685B1 (bg) Състави и методи за стимулиране растежа и диференциацията на мегакариоцитите
HU200793B (en) Genetic engineering technique for producing new, human interleukin-2 protein
KR100439290B1 (ko) 인터로이칸-18을인식하는신규의폴리펩티드
AU733964B2 (en) Novel flt-3 receptor agonists
US6171824B1 (en) Hybrid cytokines
US6319691B1 (en) Fusion proteins comprising IFN-alpha2b and TM-alpha1
KR100468553B1 (ko) 고친화성 인터루킨-4 뮤테인
CN100457778C (zh) 睫状神经营养因子(cntf)突变体及其生产方法和其用途
US6465616B1 (en) Interleukin-5 antagonist
EP0811064A2 (fr) Analogues de ligand mpl
WO1997045448A1 (fr) Antagoniste d'interleukine-5
AU723413B2 (en) An interleukin-5 antagonist
AU640686B2 (en) A megakaryocytopoietic factor
WO1994003492A1 (fr) Variantes de l'interleukine-6 et leurs utilisations
EP0410751B1 (fr) Gène codant pour M-CSF et systèmes recombinants pour cela
MXPA99003874A (es) Agonistas del receptor de eritropoyetina circularmente permutados

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020116

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1018904

Country of ref document: HK